Akebia Therapeutics Upgraded to Hold by Zacks Research
Akebia Therapeutics (NASDAQ:AKBA), a biopharmaceutical company focused on kidney disease treatments, was upgraded from a strong sell to a hold…
1,277€
-2,48%
Echtzeit-Aktienkurs Akebia Therapeutics Inc.
Bid:
Ask:
Nachrichten zur Akebia Therapeutics Inc. Aktie
Akebia Therapeutics, Inc. (AKBA) Discusses Pipeline Progress and Strategic Focus on Kidney Disease Treatments at R&D Day - Slideshow
…
Akebia Therapeutics, Inc. (AKBA) Discusses Pipeline Progress and Strategic Focus on Kidney Disease Treatments at R&D Day Transcript
…
Akebia Therapeutics, Inc. (AKBA) Presents at Leerink Global Healthcare Conference 2026 Transcript
…
Akebia Therapeutics, Inc. (AKBA) Q4 2025 Earnings Call Transcript
…
Akebia Therapeutics, Inc. (AKBA) Q2 2025 Earnings Call Transcript
…
Is Akebia Therapeutics (AKBA) the Best Stock to Invest in for a Stock Market Game?
We recently published a list of 12 Best Stocks to Invest in for a Stock Market Game. In this article,…
Akebia Therapeutics (AKBA): BTIG sieht 316 % Kurspotenzial - Potenzial im CKD-Markt wird gemäß des Experten erheblich unterschätzt!
Akebia Therapeutics Inc. (AKBA) ist ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung und Vermarktung von Therapien für Patienten mit…
Akebia Therapeutics, Inc. (AKBA) Q2 2024 Earnings Call Transcript
…